35 / 59
•
Enzalutamide and apalutamide have demonstrated a significant benefit
in Metastases-free survival, primary endpoint in PROSPER and SPARTAN
vs. placebo, with HR 0.29 and 0.28, and median MFS of 36.6 and 40.5
months, respectively.
•
Also, benefit was present in secondary objectives.
•
Positive results for darolutamide vs. placebo in ARAMIS trial have been
reported and are expected to be communicated in 2019 ASCO GU.
•
However, some caveats may be considered.
PIVOTAL TRIALS IN M0 CRPC